The Good, Bad, and Ugly

Therapeutic Use of KASPER and Urine Drug Screening and Testing in Clinical Practice

Activity Details
  • Credit Amounts:
    • CME: 0.75
    • Other: 0.75
  • Cost: Free
  • Release: Oct 31, 2014
  • Expires: Aug 16, 2019
  • Estimated Time to Complete:
    45 Minutes
  • System Requirements:
  • Average User Rating:
    (20 Ratings)


Michelle R.  Lofwall Michelle R. Lofwall, MD, DFASAM
Associate Professor, Psychiatry and Behavioral Science
Center on Drug and Alcohol Research
University of Kentucky College of Medicine
Lexington, Kentucky

Needs Statement

KASPER and UDS/T can be used as therapeutic clinical tools to help monitor for unintended adverse effects of prescribed opioids (and other controlled drugs with known abuse potential and increasing presence in overdose death cases such as the opioids and benzodiazepines) and to help health providers not be unintentional sources of diverted medications. This process can get providers talking more to patients (and their family/friends) about the need for safe storage, diversion, misuse, and substance use disorder that impacts patients and public health.

Target Audience

This activity is designed for prescribers of controlled substances including physicians, nurse practitioners, and dentists and any other interested health care professionals.


Upon completion of this educational activity, you will be able to:
  • Interpret and verify a KASPER report
  • Understand how to have appropriate conversations with patients about unexpected KASPER report results 
  • Review metabolism of commonly prescribed pain pills that can affect interpretation of urine drug test and give case examples of common misinterpreted results
  • Explain the differences between urine screens vs. tests


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, Operation UNITE, and Kentucky Office of Drug Control Policy. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

This training has been approved by the KBML as meeting the statutory requirements of HB1.

ACGME Competencies

  • Patient care

UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

Faculty Disclosure

Michelle R. Lofwall, MD, (speaker and planner) has relevant financial relationships with commercial interests as follows:
Orexo, Consultant, Consultant Fee
PCM Scientific, Advisory Board Member, Honorarium
The speaker does not plan to discuss the off-label use of a product.


This activity is jointly provided by the University of Kentucky, Operation UNITE, and Kentucky Office of Drug Control Policy.

Review Date


CE Content Concerns


Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504


  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.